683 related articles for article (PubMed ID: 24200492)
1. Expression profile of osteoprotegerin, RANK and RANKL genes in the femoral head of patients with avascular necrosis.
Samara S; Dailiana Z; Chassanidis C; Koromila T; Papatheodorou L; Malizos KN; Kollia P
Exp Mol Pathol; 2014 Feb; 96(1):9-14. PubMed ID: 24200492
[TBL] [Abstract][Full Text] [Related]
2. Expression of osteoprotegerin, RNAK and RANKL genes in femoral head avascular necrosis and related signaling pathway.
Miao Q; Hao S; Li H; Sun F; Wang X
Int J Clin Exp Pathol; 2015; 8(9):10460-7. PubMed ID: 26617755
[TBL] [Abstract][Full Text] [Related]
3. [Osteoprotegerin mRNA/receptor activator of NF-kappaB ligand mRNA expressions in bone tissues of glucocorticoid-induced osteonecrosis of the femoral head].
Wang J; Wang K; Shi Z; Zhang M
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2008 Oct; 22(10):1161-4. PubMed ID: 18979868
[TBL] [Abstract][Full Text] [Related]
4. Effects of Wenyangbushen formula on the expression of VEGF, OPG, RANK and RANKL in rabbits with steroid-induced femoral head avascular necrosis.
Song HM; Wei YC; Li N; Wu B; Xie N; Zhang KM; Wang SZ; Wang HM
Mol Med Rep; 2015 Dec; 12(6):8155-61. PubMed ID: 26496816
[TBL] [Abstract][Full Text] [Related]
5. [Osteoprotegerin and receptor activator of nuclear factor kappa B ligand mRNAs expression in BMSCs of glucocorticoid-induced necrosis of the femoral head patients].
Wang J; Gao H; Wang K; Li W; Shi Z; Zhang M
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2009 Jul; 23(7):777-80. PubMed ID: 19662974
[TBL] [Abstract][Full Text] [Related]
6. Effects of osteoprotegerin, RANK and RANKL on bone destruction and collapse in avascular necrosis femoral head.
Xiong MY; Liu LQ; Liu SQ; Liu ZH; Gao HF
Am J Transl Res; 2016; 8(7):3133-40. PubMed ID: 27508034
[TBL] [Abstract][Full Text] [Related]
7. [Effect of Epimedium extract on osteoprotegerin and RANKL mRNA expressions in glucocorticoid-induced femoral head necrosis in rats].
Wang JZ; Gao HY; Wang KZ; Zhou RX; Li XD; Guo J; Lv HC
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Oct; 31(10):1714-7. PubMed ID: 22027774
[TBL] [Abstract][Full Text] [Related]
8. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
[TBL] [Abstract][Full Text] [Related]
9. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas.
Mikami S; Katsube K; Oya M; Ishida M; Kosaka T; Mizuno R; Mochizuki S; Ikeda T; Mukai M; Okada Y
J Pathol; 2009 Aug; 218(4):530-9. PubMed ID: 19455604
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-145 Mediates Steroid-Induced Necrosis of the Femoral Head by Targeting the OPG/RANK/RANKL Signaling Pathway.
Zhao JJ; Wu ZF; Wang L; Feng DH; Cheng L
PLoS One; 2016; 11(7):e0159805. PubMed ID: 27459539
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-34a alleviates steroid-induced avascular necrosis of femoral head by targeting Tgif2 through OPG/RANK/RANKL signaling pathway.
Peng WX; Ye C; Dong WT; Yang LL; Wang CQ; Wei ZA; Wu JH; Li Q; Deng J; Zhang J
Exp Biol Med (Maywood); 2017 Jun; 242(12):1234-1243. PubMed ID: 28454497
[TBL] [Abstract][Full Text] [Related]
12. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
[TBL] [Abstract][Full Text] [Related]
13. Effects of icariin on the regulation of the OPG-RANKL-RANK system are mediated through the MAPK pathways in IL-1β-stimulated human SW1353 chondrosarcoma cells.
Wang Z; Ding L; Zhang S; Jiang T; Yang Y; Li R
Int J Mol Med; 2014 Dec; 34(6):1720-6. PubMed ID: 25270538
[TBL] [Abstract][Full Text] [Related]
14. Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review).
Liu W; Zhang X
Mol Med Rep; 2015 May; 11(5):3212-8. PubMed ID: 25572286
[TBL] [Abstract][Full Text] [Related]
15. Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice.
Cao J; Venton L; Sakata T; Halloran BP
J Bone Miner Res; 2003 Feb; 18(2):270-7. PubMed ID: 12568404
[TBL] [Abstract][Full Text] [Related]
16. [Expressions of RANK, RANKL, and osteoprotegerin in male rats at different ages].
Zhou XW; Liu YC; Jian XC; Lei YH; Wu Y
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Sep; 31(9):1539-42. PubMed ID: 21945761
[TBL] [Abstract][Full Text] [Related]
17. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women.
Kim JG; Kim JH; Kim JY; Ku SY; Jee BC; Suh CS; Kim SH; Choi YM
Menopause; 2007; 14(5):913-8. PubMed ID: 17667143
[TBL] [Abstract][Full Text] [Related]
18. [Genomic approaches to bone and joint diseases. Mutations of RANK, OPG and RANKL genes found in humans].
Kobayashi Y; Takahashi N
Clin Calcium; 2008 Feb; 18(2):202-9. PubMed ID: 18245890
[TBL] [Abstract][Full Text] [Related]
19. Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression.
Schubert A; Schulz H; Emons G; Gründker C
Gynecol Endocrinol; 2008 Jun; 24(6):331-8. PubMed ID: 18584413
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen stimulates osteoprotegerin production and inhibits receptor activator of nuclear factor-kappaB ligand expression by human osteoblasts.
Yonou H; Horiguchi Y; Ohno Y; Namiki K; Yoshioka K; Ohori M; Hatano T; Tachibana M
Prostate; 2007 Jun; 67(8):840-8. PubMed ID: 17394194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
